Key result
Hyperbaric oxygen therapy reduces oxidative stress, inflammation, and apoptosis in pre-clinical acute ischemic stroke.
Stroke serves as a life-threatening disease and continues to face many challenges in the development of safe and effective therapeutic options. The use of hyperbaric oxygen therapy (HBOT) demonstrates pre-clinical effectiveness for the treatment of acute ischemic stroke and reports reductions in oxidative stress, inflammation, and neural apoptosis. These pathophysiological benefits contribute to improved functional recovery. Current pre-clinical and clinical studies are testing the applications of HBOT for stroke neuroprotection, including its use as a preconditioning regimen. Mild oxidative stress may be able to prime the brain to tolerate full extensive oxidative stress that occurs during a stroke, and HBOT preconditioning has displayed efficacy in establishing such ischemic tolerance. In this review, evidence on the use of HBOT following an ischemic stroke is examined, and the potential for HBOT preconditioning as a neuroprotective strategy. Additionally, HBOT as a stem cell preconditioning is also discussed as a promising strategy, thus maximizing the use of HBOT for ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Cozene et al. (2020) conducted a review in Acute ischemic stroke. Hyperbaric oxygen therapy (HBOT) and HBOT preconditioning was evaluated. Hyperbaric oxygen therapy and preconditioning show pre-clinical efficacy in reducing oxidative stress, inflammation, and neural apoptosis in acute ischemic stroke (no quantitative data reported).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: